When specialists propose screening guidelines for primary care clinicians to implement, differences in perspectives between the 2 groups can create confl icts. Two recent specialty organization guidelines illustrate this issue. The American Urological Association guideline panel and National Comprehensive Cancer Network recommend that average-risk men fi rst be counseled about the risks and benefi ts of prostate-specifi c antigen screening for prostate cancer at age 40 rather than at the previously recommended age of 50 years. There is no direct evidence, however, that this recommendation has any impact on prostate cancer-specifi c mortality. To avoid distracting primary care clinicians from providing services with proven benefi t and value for patients, professional organizations should follow appropriate standards for developing guidelines. Primary care societies and health care systems should also be encouraged to evaluate the evidence and decide whether implementing the recommendations are feasible and appropriate. 
Rationale for Screening at an Earlier Age
Owing to inconclusive evidence, past prostate cancer screening guidelines from specialist physicians have differed sharply from those of generalist clinicians. [1] [2] [3] By applying better evidence, screening recommendations have converged toward a consensus that men should be informed of the benefi ts and harms of screening. Now, however, 2 prominent specialty groups have issued guidelines that adhere to the spirit of informed decision making, but have extended the recommendations to younger men. These guidelines illustrate the consequences of confl icting perspectives.
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In 2009, the American Urological Association (AUA) released a guideline on prostate-specifi c antigen (PSA) screening for prostate cancer. 4 The guideline, developed by a multidisciplinary panel largely composed of specialists, departed from the previous recommendation to begin addressing screening with average-risk men at age 50 years, stating that "… the age for obtaining a baseline PSA test [in a wellinformed patient] has been lowered to 40 years." The National Comprehensive Cancer Network (NCCN), which convened a multidisciplinary panel dominated by specialists, also recommended offering average-risk men baseline PSA testing at age 40 years. 5 The AUA and NCCN guidelines are intended for health care professionals who counsel patients about screening. Because most people receive preventive services in the primary care setting, the responsibility for implementing these guidelines will fall largely to primary care clinicians. Explaining the benefi ts and harms of PSA screening entails a potentially time consuming discussion, but often this type of discussion does not take place. [6] [7] [8] The US Preventive Services Task Force (USPSTF) currently recommends delivering 35 adult preventive services, for which it found high certainty of moderate or high net benefi t. 9 Investigators have estimated that it would require 7.4 hours a day for primary care physicians to provide these recommended services. 10 Given the limited time in a typically rushed primary care visit, is there suffi cient evidence that the net benefi ts of starting PSA screening at age 40 years justify additional counseling time?
Evidence for Screening at an Earlier Age
The most recent AUA and NCCN guidelines were released after the 2009 publication of 2 large randomized screening trials, the US Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) 11 and the European Randomized Study of Screening for Prostate Cancer (ERSPC). 12 In the PLCO, which enrolled men aged 50 to 74 years, screening did not reduce prostate cancer mortality, though screening was widespread among the control group. 11 The ERSPC, which had less contamination, reported that screening signifi cantly reduced prostate cancer mortality by 20% among men aged 55 to 69 years. 12 The absolute mortality risk reduction with screening, however, was less than 1 per 1,000 men, implying that more than 1,400 men needed to be screened to prevent 1 prostate cancer death in 9 years of follow-up. The small mortality reduction with screening must be weighed against its potential harms, including false-positive tests, overdiagnosis, and treatment complications. 13 What do the epidemiology of prostate cancer and these results say about the wisdom of extending PSA screening to men aged 40 years? Of 29,093 US prostate cancer deaths in 2007, nearly 96% occurred among men aged 60 years and older; only about 100 deaths (and just under 3% of incident cases) occurred in men aged 50 years and younger.
14 Although we lack direct evidence that a baseline PSA at age 40 years reduces the mortality toll after age 60 years, the ERSPC provides hints to the contrary. While not included in the estimate of screening effi cacy, men aged between 50 and 54 years were randomized in the ERSPC. After about 55,000 personyears of follow-up, only 6 prostate cancer deaths had occurred in the screening group and 4 in the control group. 12 A decision model study based on ERSPC and population data suggested that the lifetime benefi t of beginning routine screening for average-risk men at age 40 rather than age 50 years would be less than 1 fewer prostate-cancer deaths per 1,000 men. 15 The remaining arguments for discussing earlier screening rely on weak indirect evidence. The NCCN made a category 2B recommendation (nonuniform consensus based on "lower-level evidence") based on the rationale that fi rst offering PSA testing at the age of 40 years could prevent "tragic, untimely early deaths." 5 The AUA guideline speculated that being diagnosed in their 40s might cure some additional men destined to die at age 55 to 64 years. 4 They reasoned that these younger men might have more "curable" cancer than older men based on observational data showing more favorable tumor characteristics and lower risk for PSA progression after radical prostatectomy. [16] [17] [18] This contention cannot be proved without controlled trials documenting greater survival with aggressive treatment. Another justifi cation is that the higher specifi city of PSA in younger men might reduce the number of prostate biopsies. 19 Unfortunately, the common practice of lowering the PSA biopsy threshold for men in their 40s to increase test sensitivity inevitably reduces specifi city. 20 Finally, the AUA authors assert that obtaining a PSA level at 40 years can establish a baseline for calculating PSA velocity and determining subsequent screening intervals. Analyses of the ERSPC 21 and the Prostate Cancer Prevention Trial 22 data, however, show that measuring PSA velocity does not appreciably improve the predictive value of total PSA.
These arguments supporting prostate screening at 40 years seem weak in the face of epidemiologic reality, decision modeling, and the evidence from the ERSPC. Tellingly, the American Cancer Society, which has often recommended cancer screening when more conservative guidelines have not, recommends in its most recent screening guidelines holding screening discussions before 50 years only with men in high-risk C ANCER SCREENING: PRIMARY C ARE VS SPECIALIST populations (African Americans, positive family history in fi rst-degree relatives). 19 In May 2012, the USPSTF issued recommendations against screening any healthy man, regardless of age, race, or family history.
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DEVELOPING GUIDELINES FOR SCREENING AND PREVENTION RELEVANT TO PRIMARY CARE
Viewed narrowly, the 2 specialty guidelines appear to be well-meaning efforts that, although based on untested hypotheses rather than direct evidence, might marginally reduce prostate cancer morbidity and mortality. More broadly, however, to propose screening strategies without any direct evidence of benefi t takes us in the wrong direction-away from what has been a generally rising standard of evidence-and toward accepting expert opinion as adequate grounds for recommending procedures that expose many to the risk of harms for the benefi t of very few.
A direct consequence of following the AUA and NCCN recommendations would be to enlarge the population being counseled about screening. This outcome would reduce the time available for implementing proven screening and preventive services in primary care. Furthermore, when the legal system argues that such guidelines represent the community standard of care, primary care clinicians who fail to follow them may be exposed to unjustifi ed medical-legal action. 24 Notably, the AUA has been aggressively targeting the media, lawmakers, and patients with proscreening messages after the release of the USP-STF recommendation. 25 Ideally, groups that develop guidelines will eventually achieve consensus on methodological issues, such as the optimal composition of expert panels, deciding what scientifi c evidence is strong enough to be admissible, and how to avoid going beyond the evidence when making practice recommendations. To strengthen the guideline development process, generalist clinicians and experts in evidence synthesis should be included on guideline panels and on external review panels. Guidelines should be based on systematic review of the evidence, and not based solely on expert opinion. Widespread use of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for categorizing the quality of evidence and the strength of recommendations would be an important step in the right direction. 26 The Institute of Medicine recently issued performance standards for practice guideline developers (Table 1) , 27 and the American Cancer Society has committed to following these principles. 28 Most primary care clinicians lack the time to study guidelines and form independent opinions about them. In an important trend, primary care professional societies have begun to vet specialty guidelines. The American College of Physicians is developing Clinical Guidance Statements 29 and the American Academy of Family Physicians 30 has implemented evidence-based processes for evaluating guidelines developed by other organizations. The publication of rigorous GRADE and Institute of Medicine standards for developing and assessing the credibility of guidelines along with primary care professional society efforts to fi lter specialty guidelines are encouraging signs. This support will empower clinicians to choose which guidelines belong in primary care practice, enabling them to focus on providing services with proven effectiveness and value to their patients. 
